Combat Effectiveness Boosted Fivefold! New "Smart" Immune Cells Precisely Target and Eliminate Cancer Cells
Release time:
2025-04-18
Imagine if immune cells in the human body could transform into "smart missiles," relentlessly tracking and destroying cancer cells without harming healthy tissue—this would revolutionize cancer treatment. A groundbreaking announcement from the USC Viterbi School of Engineering reveals the arrival of "EchoBack CAR T cells", a new breed of "thinking" immune warriors propelling targeted cancer therapy into a 2.0 era!
From "Blitzkrieg" to "Prolonged Warfare": Immune Cells Upgrade Combat Tactics
While traditional CAR T-cell therapies have shown success against blood cancers, their activity often fades within 24 hours. In contrast, USC’s EchoBack cells are "endurance champions": a single ultrasound activation keeps them battle-ready for five days, continuously releasing anti-cancer munitions.
"With first-generation cells, patients might need daily hospital visits. But the new cells could reduce treatment frequency to biweekly sessions, or even less," explains Longwei Liu, Assistant Professor at USC Viterbi.
In prostate cancer and glioblastoma mouse models, two rounds of ultrasound stimulation boosted tumor clearance efficiency by 300% compared to conventional therapies. Remarkably, as cancer cells counterattack, these "smart hunters" grow fiercer, producing more lethal molecules.
Precision Navigation + Self-Destruct Protocol: Dual Safeguards for Safety
The breakthrough lies in an "ultrasound switch" design:
Targeted Activation: A 10-minute, non-invasive ultrasound pulse pinpoints tumor regions, acting like GPS for CAR T cells.
Intelligent Recognition: Activated cells deploy "molecular probes" to track cancer cells like heat-seeking missiles.
Safe Self-Destruction: Anti-cancer receptors degrade automatically post-mission, preventing collateral damage.
"This is a true breakthrough," adds Yingxiao Wang, Chair of USC’s Alfred E. Mann Department of Biomedical Engineering. "It paves the way for ultrasound-controlled CAR T therapies to become clinically viable."
From Lab to Clinic: A New Era in Cancer Treatment
The technology has shown promise across multiple solid tumor models. The team is advancing clinical trials and aims to adapt this modular platform for other cancers, such as breast cancer and retinoblastoma.
Published in Cell, this study not only redefines CAR T therapy but also expands the boundaries of precision medicine. If successfully translated, this "perpetual-motion-like" smart immunotherapy could slash treatment frequency and side effects, offering hope for advanced solid tumor patients. As the researchers declare: "This isn’t just an upgrade—it’s a complete paradigm shift in cancer treatment."
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
